Will you bet on these? Pan American Silver Corp. (PAAS), Synergy Pharmaceuticals, Inc. (SGYP)

0

The shares of Pan American Silver Corp. (NASDAQ:PAAS) and Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) were among the active stocks of the last trading sessions. Pan American Silver Corp. (NASDAQ:PAAS) soared to 5.59% closing at the price of $15.49 whereas the shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) soared 3.76% with the increase of 0.05 points closing at the price of $1.38. Pan American Silver Corp. has currently decrease -6.86% in its stock over the period of 6-months while its rival Synergy Pharmaceuticals, Inc. subtracted -23.76% in the previous 6-months.

Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.

Returns and Profitability

Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.

The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of Pan American Silver Corp. (NASDAQ:PAAS) is 8.5% while the ROI of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) is -201.1%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, PAAS’s EBITDA Margin is 6.94 whereas SGYP’s is -2.8.

Both the profitability ratios suggest that Pan American Silver Corp. (NASDAQ:PAAS) is more suitable investment in terms of profitability and return.

EPS & Surprise Factor

Pan American Silver Corp. (NASDAQ:PAAS) reported $0.23/share EPS for the previous quarter where analysts were predicting an EPS to be $0.14/share Thus beating the analyst Estimates with a Surprise Factor of 64.3 Percent. While, Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) reported EPS of $-0.12/share in the last quarter. The analysts projected EPS of $-0.15/share depicting a Surprise of 20 Percent.

Taking a look at Earnings per Share, Pan American Silver Corp. tends to be beating the analyst estimates more than Synergy Pharmaceuticals, Inc.. so PAAS is more profitable than SGYP.

Technical Analysis of Pan American Silver Corp. & Synergy Pharmaceuticals, Inc.

Moving average convergence divergence (MACD) shows that Pan American Silver Corp. (NASDAQ:PAAS) is on a PRICE RELATIVITY trend While Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the Pan American Silver Corp. was in BULLISH territory and Synergy Pharmaceuticals, Inc. was in BEARISH territory.

PAAS’s current statistics gauge that the stock candle is BULLISH with HIGH volatility. While SGYP’s candle is BULLISH with HIGH.

EPS Growth Rate: PAAS’s 9.57% versus SGYP’s 0%

Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of Pan American Silver Corp. (NASDAQ:PAAS) is predicted at 9.57% while Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) stands at 0%. These numbers suggest that PAAS is more suitable investment in terms of EPS growth rate.

Financial Risk and Liquidity Concerns

The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of PAAS stands at 4.1 while SGYP is at 2.8 whereas the debt ratio of the prior is 0.01 while the debt ratio of the later is 0.

The values of the both ratios suggest that PAAS is more suitable investment when the liquidity and risk is the main concern.

Analyst Recommendations

While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 2.3 for PAAS and 2 for SGYP which means PAAS has Hold rating whereas SGYP has Buy rating.

Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for PAAS is $19.42 which is 20.24% of its current price while SGYP has price target of 6.24 which is 77.88% of its current price.

Valuation Ratios

Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.

PAAS currently has price to earning P/E ratio of 15.89 whereas SGYP has 0 while the forward P/E ratio for the prior stands at 23.58 and for the later it depicts the value of 0.

The price to Book P/B for PAAS is 1.49, Price to Sale is at 2.83 and for SGYP these ratios stand at 0 and 9.79.